Ranbaxy Laboratories Limited (Ranbaxy) is a research based international pharmaceutical company serving customers in over 150 countries. For more than 50 years, we have been providing high quality, affordable medicines trusted by healthcare professionals and patients across geographies.

Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.
Read More

Ranbaxy hightlights improved Business Standards and Quality Assurance initiatives

DEDICATED TO PROVIDING SAFE AND EFFICACIOUS MEDICINES GLOBALLY

Ranbaxy Laboratories Ltd. today highlighted some of the major specific actions the Company has been taking in recent years to address certain conduct of the past and to ensure the safety and efficacy of all Ranbaxy products currently available in the global market.
Read More

Explore Ranbaxy

Latest News

Press Statement
May 31, 2013: Gurgaon,Haryana: Ranbaxy today issued an advisory in public interest for Patients, Doctors and all its stakeholders. All Ranbaxy products currently…
Edit
RANBAXY HIGHLIGHTS IMPROVED BUSINESS AND QUALITY ASSURANCE STANDARDS
May 22, 2013: DEDICATED TO PROVIDING SAFE AND EFFICACIOUS MEDICINES GLOBALLY Gurgaon, India, May 22, 2013: Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE:…
Edit
Ranbaxy Announces Conclusion Of Previously Disclosed Investigation By U.S. Department Of Justice
May 13, 2013: Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), today announced that a previously disclosed investigation by the U.S. Department…
Edit
Ranbaxy Q1 CY 2013 Sales Rs.24,398 Mn. Base business grows by over 10%
May 08, 2013: Focus continues in branded markets and differentiated products The Board of Directors of Ranbaxy Laboratories Limited (RLL, NSE: RANBAXY, BSE:…
Edit
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
Apr 17, 2013: Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced synergy in Brazil to expand…
Edit
Update on Atorvastatin Recall in USA
Mar 26, 2013: On March 26, 2013, Ranbaxy Pharmaceuticals Inc., the U.S. subsidiary of Ranbaxy Laboratories Limited, resumed the supply of Atorvastatin calcium…
Edit
Ranbaxy to market Desvenlafaxine Base Extended Release Tablets in The U.S.
Mar 05, 2013: Enters into an in-licensing business agreement with Alembic Princeton, NJ – March 05, 2013 — Ranbaxy Pharmaceuticals Inc. (RPI), a…
Edit
RANBAXY SURPASS 2012 GUIDANCE; CROSSES RS.120 BN IN GLOBAL SALES
Feb 26, 2013: Q4 CY 2012 Sales Rs.26,708 Mn CY 2012 Sales Rs.123 Bn, EBITDA Rs.18,227 Mn EBITDA margin 15%. Sales growth of…
Edit